Volume 7 Supplement 2

13th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint Meeting with the Austrian Society of Toxicology (ASTOX) and the Hungarian Society for Experimental and Clinical Pharmacology (MFT)

Open Access

Heterologous expression of membrane proteins in cardiac myocytes

  • Miroslav Radenkovic1Email author,
  • Halyna Pankevych1,
  • Oliver Kudlacek1,
  • Ingrid Gsandtner1 and
  • Karlheinz Hilber1
BMC Pharmacology20077(Suppl 2):A6

DOI: 10.1186/1471-2210-7-S2-A6

Published: 14 November 2007

The cardiac isoform of the Na+ channel (NaV1.5) is known to accumulate in the endoplasmic reticulum (ER). This retention presumably reflects quality control in the ER. In order to understand the underlying mechanism, we heterologously expressed the human orthologue of the Na+ channel (NaV1.5) in neonatal primary rat and murine cardiomyocytes, in a cardiomyoblast cell line (H9c2) and in HEK293 cells (internal control). In HEK293 cells, NaV1.5 readily accumulated at the cell surface and gave rise to functional channels with the expected electrophysiological properties. In contrast, in cardiomyocytes and H9c2 cells, the NaV1.5 accumulated in the ER regardless of the transfection method employed (lipofection, nucleofection). As a positive control, we employed G protein-coupled β1-adrenergic, A1 and A2A adenosine receptors. In HEK293 cells, export of the A2A receptor is known to be enhanced by the deubiquinating enzyme USP4. Accordingly, we also co-expressed USP4 and the A2A receptor in the different cardiomyocyte preparations. However, in all instances, the membrane proteins were trapped within intracellular compartments. This was, in particular true for the NaV1.5, which, in many instances, accumulated in circular bodies, which are reminiscent of calnexin-rich organized smooth ER structures. Based on these findings, we conclude that (i) membrane proteins undergo stringent quality control in cardiac myocytes and (ii) ER-export of the NaV1.5 is limited by the availability of additional cardiomyocyte-specific components.

Declarations

Acknowledgements

Supported by FWF M989-B09 (MR) and ÖAW DOC-fFORTE 22255 (IG).

Authors’ Affiliations

(1)
Department of Pharmacology, Center of Biomolecular Medicine and Pharmacology, Medical University of Vienna

Copyright

© Radenkovic et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd.

Advertisement